

# Pioneering Biosimilar Access for Patients

Biosimilars are FDA-approved medicines that match their reference biologic in terms of efficacy, safety, and quality, can generate savings for patients, and:



- ✓ Enhance patient access to more affordable versions of biologic medicines
- ✓ Create sustainability for overburdened health systems by increasing savings and making room for innovation and new medicines
- ✓ Lower the cost of biologics by encouraging competition in the biologics market<sup>1</sup>

As of June 2021,

## 29 biosimilars

have been approved by the FDA<sup>2</sup>



Patients who took certain biosimilars paid on average up to

## 45% less

out-of-pocket than those who took the reference product<sup>3</sup>



As a result of increased biosimilar availability, an estimated

## 1.2 million additional US patients

could gain access to the life-changing biologic medicines they need by 2025<sup>4</sup>



Biosimilar medicines could deliver up to

## \$183 billion in savings

to payers and the US healthcare system over 5 years (2021–2025). With these savings, health systems could reallocate resources to improve patient care.<sup>5</sup>



US biosimilars savings totaled

## \$4.5 billion

over the last 10 years, with accelerated savings of

## \$2.2 billion

in 2019 alone<sup>6</sup>



Large\* US employers could

## save up to \$1.4 billion a year

and realize significant savings for their employees by promoting the use of biosimilars in employee-sponsored health plans<sup>3</sup>



\*According to the Affordable Care Act, a large employer is defined by having at least 50 full-time employees<sup>7</sup>

**Advocating for legislation and programs that support access to biosimilar medicines can help improve patient access and increase savings. The adoption of focused, common sense federal and state policies will ensure the sustainability of the biosimilar medicines market and that patients receive the medicines they need.**

**Learn more at [www.us.sandoz.com/biosimilars](http://www.us.sandoz.com/biosimilars).**

<sup>1</sup> Biosimilars Forum. Biosimilars Have Significantly Lowered Prices of All Biologics. Published April 2021. Accessed May 14, 2021.

<sup>2</sup> US Food and Drug Administration. Biosimilar Product Information. <https://www.fda.gov/drugs/biosimilars/biosimilar-product-information>. Accessed May 12, 2021.

<sup>3</sup> Social M, Ballreich J, Chyr L, Anderson, G. Biosimilar Medications—Savings Opportunities for Large Employers. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management; 2020. [https://www.eric.org/wp-content/uploads/2020/03/JHU\\_Savings-Opportunities-for-Large-Employers.pdf](https://www.eric.org/wp-content/uploads/2020/03/JHU_Savings-Opportunities-for-Large-Employers.pdf).

<sup>4</sup> Biosimilars Council. Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines. Published September 2017.

<sup>5</sup> IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. Published September 29, 2020. Accessed May 12, 2021.

<sup>6</sup> Association for Accessible Medicines. 2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. September 29, 2020. <https://accessiblemeds.org/sites/default/files/2020-09/AAM-2020-Generics-Biosimilars-Access-Savings-Report-US-Web.pdf>

<sup>7</sup> Internal Revenue Service. Affordable Care Act Tax Provisions for Employers. Published January 22, 2022. Accessed August 17, 2021. <https://www.irs.gov/affordable-care-act/employers>